Menlo Park, California, February 19, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Rekha Hemrajani has joined the Company as its Chief Financial Officer, SVP of Business and Financial Operations. Ms. Hemrajani, who was formerly the Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals, has been serving as a consultant to biotech companies and investors since Amgen acquired Onyx in October, 2013.
“It is a pleasure to welcome Rekha to 3-V. Her healthcare sector expertise and experiences across corporate development, finance and operations will be a tremendous asset to the team as we advance the Company to its next stage of growth,” commented Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.
Prior to joining 3-V, Ms. Hemrajani spent the past fourteen years in the healthcare industry most recently as Vice President, Head of Licensing and M & A Group at Onyx Pharmaceuticals. In this capacity, she was responsible for corporate development strategy, search and evaluation, financial forecasting and analysis, competitive intelligence and transaction execution. Previously, she was Vice President of Business Development at Exelixis where she was involved in raising over $800 million in capital through business development and other non-dilutive transactions. Before Exelixis, she spent a cumulative six years in investment banking at Credit Suisse First Boston and Lehman Brothers helping large, small and mid-sized companies in the biopharmaceutical and healthcare industries raise capital in the public and private markets, as well as with mergers and acquisitions. Ms. Hemrajani received her MBA from the Kellogg Graduate School of Management, Northwestern University and holds a B.S. in Economics and Computer Science from the University of Michigan.
About 3-V Biosciences
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company’s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V’s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.
# # #
Investor Relations Contact:
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103